Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that a Meeting of the Board of Directors of the Company will be held on Wednesday, November 4, 2026, to consider and approve inter alia, the following: 1. Standalone & Consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2026, and 2. Payment of Interim Dividend, if any, for the financial year 2026-27. Further to its letter dated September 24, 2026, whereby the company informed the closure of Trading Window of the Company from October 1, 2026, until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2026, the company has informed that the Trading Window will remain closed up to November 6, 2026 and shall be re-opened on November 7, 2026.
The above information is a part of company’s filings submitted to BSE.
